In the past week, NVNO stock has gone down by -4.32%, with a monthly gain of 14.99% and a quarterly surge of 54.05%. The volatility ratio for the week is 4.55%, and the volatility levels for the last 30 days are 8.54% for enVVeno Medical Corporation The simple moving average for the past 20 days is -3.58% for NVNO’s stock, with a 19.63% simple moving average for the past 200 days.
Is It Worth Investing in enVVeno Medical Corporation (NASDAQ: NVNO) Right Now?
The 36-month beta value for NVNO is also noteworthy at 1.00. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The public float for NVNO is 17.37M, and at present, short sellers hold a 2.48% of that float. The average trading volume of NVNO on July 04, 2025 was 104.27K shares.
NVNO stock’s latest price update
enVVeno Medical Corporation (NASDAQ: NVNO) has experienced a rise in its stock price by 1.01% compared to its previous closing price of $3.95. However, the company has seen a fall of -4.32% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-06 that Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT – Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below).
NVNO Trading at 7.27% from the 50-Day Moving Average
After a stumble in the market that brought NVNO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.43% of loss for the given period.
Volatility was left at 8.54%, however, over the last 30 days, the volatility rate increased by 4.55%, as shares surge +8.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +52.87% upper at present.
During the last 5 trading sessions, NVNO fell by -4.32%, which changed the moving average for the period of 200-days by -25.84% in comparison to the 20-day moving average, which settled at $4.14. In addition, enVVeno Medical Corporation saw -22.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVNO starting from Duhay Francis, who purchase 81,433 shares at the price of $3.07 back on Dec 31 ’24. After this action, Duhay Francis now owns 102,344 shares of enVVeno Medical Corporation, valued at $249,999 using the latest closing price.
Gray Robert, the Director of enVVeno Medical Corporation, purchase 3,500 shares at $2.94 during a trade that took place back on Dec 31 ’24, which means that Gray Robert is holding 11,155 shares at $10,290 based on the most recent closing price.
Stock Fundamentals for NVNO
Current profitability levels for the company are sitting at:
- -28.67% for the present operating margin
- 0.17% for the gross margin
The net margin for enVVeno Medical Corporation stands at -26.27%. The total capital return value is set at -0.6%. Equity return is now at value -52.88%, with -49.95% for asset returns.
Based on enVVeno Medical Corporation (NVNO), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -17.68.
Currently, EBITDA for the company is -21.29 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 83.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.77.
Conclusion
In summary, enVVeno Medical Corporation (NVNO) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
